Biosign

Toronto, July 2, 2010 / PRNewswire / - Biosign Technologies Inc. (CNSX: BIO) today has announced the signing of an exclusive master distribution agreement with Dynamicare AG, based in Switzerland, for the distribution of Biosign products in Switzerland in Switzerland, Germany, France and Austria, with an expanded distribution option in Europe.According to the terms of the agreement, Dynamicare will pay an initial rate of 2.5 million Canadian dollars, with a commitment to get sales of more than 100 million Canadian dollars for 2011.

The initial rate will be paid when the Pilot Mercado Pilot Agreement (R) TEN-20 is satisfied at the end of October 2010. The pilot agreement will create immediate marketing opportunities within the selected markets, while highlighting the main factors that willThey include in distribution and deployment decisions, such as support for high volume use, multiple languages ​​and 'clients' tests and'.

Biosign plans to deploy its products and services with Dell and Dell Services worldwide.Dell has classified the first in customer service, and it is undoubtedly the largest health company in the world, becoming the logical choice for the launch of products in Europe.

Patrick Dressel, General Director of Dynamicare, declared: "Dynamicare focuses on providing innovative solutions for diabetics. The UFIT (R) platform is the next evolution of tests and diagnoses for personal medicine, promising a momentary impact on controlof diabetes in terms of cost, comfort and precision.

UFIT (R) TEN-20 is an online medical instrument for the self-control of blood pressure and blood glucose.The instrument takes the pulse on the wrist through an inflatable fist, and provides the results of blood pressure and blood glucose.All evaluations are indirect, non -invasive and passive.The results are stored on Biosign servers with the test sample.

Radu Leca, General Director of Biosign, commented: "Europe represents the third part of our world market. It is superior to the rest in terms of providing the best general health treatment, with France, Austria, Switzerland and Germany recognized as world leaders. We areHappy of the opportunity to use the cradle of a modern medicine to launch our radically unique product.in order to ensure successful launch. "

About Biosign Technologies Inc.

Biosign Technologies Inc. (CNSX: Bio) offers biomedical systems.Key applications are intelligent systems for non -invasive monitoring of common health risks associated with blood pressure, glucose and medication.Nuclear technology combines the measure, analysis and rapid knowledge training to support health monitoring in world markets.Technology for UFIT medical devices (R) enhances the collection and analysis of quality data for clinical diagnosis, self-arising, well-being, evaluation and treatment of the disease status and remote monitoring of the patient.For more information about biosign, visit